Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypertension II: Pathophysiology01:29

Hypertension II: Pathophysiology

Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Acute oral digoxin in healthy adults hastens fatigue and increases plasma K<sup>+</sup> during intense exercise, despite preserved skeletal muscle Na<sup>+</sup>,K<sup>+</sup>-ATPase.

The Journal of physiology·2024
Same author

Digoxin and exercise effects on skeletal muscle Na<sup>+</sup>,K<sup>+</sup>-ATPase isoform gene expression in healthy humans.

Experimental physiology·2024
Same author

Oral digoxin effects on exercise performance, K<sup>+</sup> regulation and skeletal muscle Na<sup>+</sup> ,K<sup>+</sup> -ATPase in healthy humans.

The Journal of physiology·2022
Same author

Risk factors for asymptomatic echocardiographic abnormalities that predict symptomatic heart failure.

ESC heart failure·2021
Same author

Insulin-like growth factor-1 directly affects cardiac cellular remodelling <i>via</i> distinct pathways.

International journal of cardiology. Heart & vasculature·2021
Same author

Kidney age - chronological age difference (KCD) score provides an age-adapted measure of kidney function.

BMC nephrology·2021

Related Experiment Video

Updated: Jun 3, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Renal denervation and hypertension.

Markus P Schlaich1, Henry Krum, Paul A Sobotka

  • 1Neurovascular Hypertension & Kidney Disease Laboratory, Baker IDI Heart & Diabetes Institute and Heart Centre, Alfred Hospital, Melbourne, Australia.

American Journal of Hypertension
|March 12, 2011
PubMed
Summary

Renal denervation, a novel procedure using radiofrequency energy to disrupt renal nerves, shows promise for managing difficult-to-treat hypertension. Further research is needed to fully understand its potential and risks for blood pressure control.

More Related Videos

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

Related Experiment Videos

Last Updated: Jun 3, 2026

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
08:35

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion

Published on: May 26, 2022

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
04:37

Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension

Published on: June 6, 2025

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Interventional Cardiology

Background:

  • Essential hypertension is a major global health challenge requiring multifactorial therapeutic strategies.
  • Current treatments, including lifestyle changes and combination pharmacotherapy, are insufficient for many patients, leaving them at high cardiovascular risk.
  • The role of renal sympathetic nerves in blood pressure regulation necessitates exploring new therapeutic avenues.

Purpose of the Study:

  • To review the scientific basis of renal denervation for hypertension management.
  • To summarize current evidence on the safety and efficacy of renal nerve ablation.
  • To identify and discuss unresolved questions regarding this interventional approach.

Main Methods:

  • Review of preclinical and clinical data on renal sympathetic nerve activity in blood pressure control.
  • Analysis of outcomes from studies involving catheter-based radiofrequency (RF) renal denervation.
  • Discussion of existing evidence regarding the safety profile and blood pressure reduction associated with the procedure.

Main Results:

  • Renal denervation utilizes RF energy to selectively target and disrupt renal sympathetic nerves.
  • Preliminary data from uncontrolled studies suggest a favorable safety profile for renal denervation.
  • The procedure is associated with substantial and potentially sustained reductions in blood pressure.

Conclusions:

  • Renal denervation presents a promising new therapeutic option for managing resistant hypertension.
  • While initial results are auspicious, further research is crucial to address numerous unanswered questions.
  • Continued investigation is required to fully elucidate the potential benefits and risks of renal nerve ablation.